Invesco
SLNO

Invesco’s Soleno Therapeutics SLNO Stock Holding History

Invesco’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-44,814
Closed -$1.5M – 3929
2026
Q1 		$1.5M Sell
44,814
-830,205
-95% -$32.5M ﹤0.01% 2683
2025
Q4 		$40.5M Sell
875,019
-625,506
-42% -$34.3M ﹤0.01% 1168
2025
Q3 		$101M Buy
1,500,525
+854,551
+132% +$63.4M 0.02% 843
2025
Q2 		$54.1M Buy
645,974
+178,781
+38% +$13.4M 0.01% 1033
2025
Q1 		$33.4M Buy
467,193
+455,181
+3,789% +$22.2M 0.01% 1193
2024
Q4 		$540K Sell
12,012
-322,157
-96% -$16.7M ﹤0.01% 3208
2024
Q3 		$16.9M Buy
334,169
+323,137
+2,929% +$15.5M ﹤0.01% 1556
2024
Q2 		$450K Sell
11,032
-308,998
-97% -$13.1M ﹤0.01% 3317
2024
Q1 		$13.7M Buy
+320,030
New +$14.5M ﹤0.01% 1643
2021
Q2 		– Sell
-2,534
Closed -$48K – 4029
2021
Q1 		$48K Buy
2,534
+109
+4% +$3.51K ﹤0.01% 3829
2020
Q4 		$70K Buy
+2,425
New +$70K ﹤0.01% 3697

Invesco's SLNO Position: Q2 2026 in Review

Invesco sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 44,814 shares — an estimated $1.5M sold.

Invesco first reported a position in SLNO in Q4 2020 and held it in 11 quarters. The position peaked at $101M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

  • Invesco reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Invesco sold 44,814 Soleno Therapeutics shares in Q2 2026, an estimated $1.5M.
  • Invesco first reported a position in Soleno Therapeutics in Q4 2020 and held it in 11 quarters.
  • Invesco's Soleno Therapeutics position peaked at $101M in Q3 2025.
  • 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.